As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > REGULATORY
REGULATORY
- Japan Approves Roche/Chugai’s Tumor-Agnostic Rozlytrek, Alnylam’s RNAi Drug and More
June 19, 2019
- LDP Inscribes AI Utilization for Drug Development in Honebuto Paper
June 19, 2019
- PMDA to Strengthen Grad/Mid-Career Hiring Strategy, Increase Operating Efficiency with AI
June 19, 2019
- 2 PMDA Advisors Infringe COI Rules; No Impact on Product Approvals
June 18, 2019
- PMDA to Prohibit Staffers from Trading Pharma Shares
June 17, 2019
- PMDA to Discuss Optimal Use of Xofluza amid Concerns over Resistant Viruses
June 17, 2019
- 10 More Hospitals to Join MID-NET Database, Covering Data on 6 Million Patients
June 17, 2019
- PMDA Reviewing Risks for Ibrance, Opdivo, Keytruda and More
June 17, 2019
- LDP’s Pharma Study Group Submits Proposal to Health Minister, Calls for PMP Revamp in 2020 Reform
June 13, 2019
- Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
June 13, 2019
- Govt’s Draft Policy Blueprint Prods Continued Debates on Pricing Reform Proposals; Expanded HTA Use, Handling of PMP-Granted Comparators and More
June 12, 2019
- PMDA Chief Mulls Requiring Few-Year Clinical Background for Reviewers
June 12, 2019
- PMDA to Form Panel on Relief System to Ensure Access, Quick Remedy
June 11, 2019
- MHLW Study Group Drafting Guidelines for New Dyslipidemia Drug Development, First in 30 Years
June 11, 2019
- Deregulation Panel Proposes Giving Private Companies Access to National Health Database to Promote New Drug Development
June 10, 2019
- MHLW Vaccine Panel Discusses Inclusion of Rotavirus Vaccine in Public Vaccination Programs; Has “Enough Data”
June 7, 2019
- Shock, Anaphylaxis Added to Xofluza’s ADR List; Label Changes for Checkpoint Blockers
June 5, 2019
- MHLW Panel Approves to Contraindicate Metformin in Impaired Kidney Function Patients with eGFR less than 30
June 4, 2019
- Reborn PMDA Boots Up under New Skipper, Bolstering “Patient First” Initiatives
June 4, 2019
- Kampo Industry Expresses Concerns over Copay Hikes, Narrow Definition of Essential Drugs: LDP League
June 3, 2019
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…